Prnewswireยท2025-06-24 12:30Core Insights - DarioHealth Corp. has presented new research demonstrating sustained outcomes for GLP-1 users and an 89% accuracy in AI-driven blood glucose predictions, indicating the company's strong position in the digital health market [1][2][6] Group 1: Research Findings - A significant reduction in eA1c levels from 9.0% to 6.7% was observed in GLP-1 users, with sustained results for six months post-medication discontinuation [2][8] - Users of Dario's platform maintained stable outcomes without significant weight or glucose rebound after stopping GLP-1 medication, addressing a critical challenge in chronic condition management [4][8] - The studies highlight the importance of integrated digital tools in enhancing medication adherence and optimizing health outcomes [5][6] Group 2: AI and Personalization - Dario's AI research achieved an 89% accuracy in predicting future blood glucose levels, utilizing user behavior and activity data [7][10] - The company's next-generation AI platform aims to provide personalized interventions based on real-time behaviors and clinical data, enhancing chronic condition management [6][9] - Age was identified as a significant factor influencing outcomes, with older adults showing stronger results through increased engagement in lifestyle activities [14] Group 3: Commercial Strategy - Dario is actively leveraging its research findings in discussions with payers and self-insured employers to offer integrated solutions for chronic condition management, particularly in GLP-1 optimization [3][10] - The company believes its platform can maximize return on investment for health plans and employers implementing GLP-1 programs, thereby enhancing commercial value [6][10]